ヒルログ

￥19800 - ￥337000
化学名: ヒルログ
英語名: Bivalirudin
別名:ヒルログ;ビバリルジン
CAS番号: 128270-60-0
分子式: C98H138N24O33
分子量: 2180.29
EINECS:274-570-6
MDL Number:MFCD08282793

価格4 プロパティ安全情報説明

4物価

選択条件：

ブランド

富士フイルム和光純薬株式会社(wako)
Sigma-Aldrich Japan

パッケージ

10mg
50mg
100mg
500mg

生産者富士フイルム和光純薬株式会社(wako)
製品番号W01BCS4049766
製品説明
英語製品説明Bivalirudin, H-D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH, Trifluoroacetate
包装単位100mg
価格￥85000
更新しました2024-03-01
購入

生産者富士フイルム和光純薬株式会社(wako)
製品番号W01BCS4049766
製品説明
英語製品説明Bivalirudin, H-D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH, Trifluoroacetate
包装単位500mg
価格￥337000
更新しました2024-03-01
購入

生産者Sigma-Aldrich Japan
製品番号SML1051
製品説明 ≥97% (HPLC)
英語製品説明Bivalirudin trifluoroacetate salt ≥97% (HPLC)
包装単位10mg
価格￥19800
更新しました2024-03-01
購入

生産者Sigma-Aldrich Japan
製品番号SML1051
製品説明 ≥97% (HPLC)
英語製品説明Bivalirudin trifluoroacetate salt ≥97% (HPLC)
包装単位50mg
価格￥79100
更新しました2024-03-01
購入

生産者	製品番号	製品説明	包装単位	価格	更新時間	購入
富士フイルム和光純薬株式会社(wako)	W01BCS4049766	Bivalirudin, H-D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH, Trifluoroacetate	100mg	￥85000	2024-03-01	購入
富士フイルム和光純薬株式会社(wako)	W01BCS4049766	Bivalirudin, H-D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH, Trifluoroacetate	500mg	￥337000	2024-03-01	購入
Sigma-Aldrich Japan	SML1051	≥97% (HPLC) Bivalirudin trifluoroacetate salt ≥97% (HPLC)	10mg	￥19800	2024-03-01	購入
Sigma-Aldrich Japan	SML1051	≥97% (HPLC) Bivalirudin trifluoroacetate salt ≥97% (HPLC)	50mg	￥79100	2024-03-01	購入

プロパティ

比重(密度) :1.52±0.1 g/cm3(Predicted)
貯蔵温度 :-20°C
溶解性 :≥54.5 mg/mL in DMSO with gentle warming; ≥10.18 mg/mL in EtOH with gentle warming and ultrasonic; ≥43.5 mg/mL in H2O with gentle warming
外見 :powder
色 :white to off-white
シーケンス :D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH
InChIKey :OIRCOABEOLEUMC-GEJPAHFPSA-N

安全情報

絵表示(GHS):

注意喚起語:

危険有害性情報:

コード	危険有害性情報	危険有害性クラス	区分	注意喚起語	シンボル	P コード

注意書き:

P261	粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避けること。
P271	屋外または換気の良い場所でのみ使用すること。
P280	保護手袋/保護衣/保護眼鏡/保護面を着用すること。

説明

Bivalirudin was launched in New Zealand as an anticoagulant for i.v. treatment of patients with unstable angina undergoing percutaneous transluminal coronary angioplasty. Bivalirubin is a synthetic 20 amino acid peptide rationally modeled on hirudin (residues 53- 64), the most potent and specific naturally-occuring known inhibitor of thrombin, the enzyme that plays a key role in hemostasis and blood clot formation. This peptide is a direct thrombin inhibitor that maintains the unique bivalent binding properties of hirudin to the catalytic site and to the fibrin-recognition exosite of the enzyme, so acting directly on thrombin with high affinity and specificity. In vitro studies demonstrated that alpha- and zeta-thrombins, both with the higher fibrinogen-procoagulant activities, were inhibited. In rats receiving high doses of bivalirudin, the platelet deposition in carotide was reduced by 63% compared to controls. The results of clinical studies, conducted only in patients receiving concomitant aspirin, suggested that the use of bivalirudin was more efficacious and more predictable than unfractionated heparin, with fewer bleeding complications. Despite some unresolved developmental issues, the attractive properties of this novel agent could make it a useful alternative to heparin in a variety of coagulation disorders.

関連製品価格